Blood: BTK inhibitor therapy can be effective in treating venetoclax drug resistance CLL
-
Last Update: 2020-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Highly active BTK inhibitors (BTKi) and BCL2 inhibitorvenetoclax change the therapeutic prospects of chronic lymphoblastic leukemia (CLL)prospective clinical trial results show that venetoclax has a good effect on patients with progression in the after-treatment of BTKi, but data on the use of BTKi treatment in CLL patients with post-treatment progression of venetoclax are limited, especially in terms of durabilitythe retrospective analysis of 23 cases of recurrent/refractory CLL cases treated with BTKi (Ilutinib: 21 cases; zanubrutinib: 2) after treatment with venetoclaxthe median progression-free survival period and median overall survival were 34 months and 42 months, respectively, after BTKi treatmentThe duration of the early remission at venetoclax was 24 months and residual lesions that were completely remissioned or could not be detected were associated with longer PFS at BTKi rescue treatment (p-values were 0.044 and 0.029, respectively)Patients with BCL2 Gly101Val Venetoclax drug-resistant mutations with BTKi therapy can achieve long-lasting results (estimated to be 69% pfS at 24 months)median follow-up for 33 months, 11 patients continued to be treated with BTKi, and 12 patients with progression (8 cases) or toxicity (4 cases) were terminatedthe results suggest that BTKi therapy can provide long-lasting course control for Patients with CLL who progresse after treatment with venetoclax
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
